GT Biopharma Restates Q3 2025 Financials, Discloses Material Weakness & Ongoing Dilution
GTBP sits 17% above its 52-week low of $0.401 on light trading volume (0.3× avg).
Summary
GT Biopharma restated its Q3 2025 financials due to material errors in liability classification, revealing a material weakness in internal controls and significant changes to reported losses. The company also reported ongoing dilutive financing activities post-period.
Key Events · Corporate Governance and Compliance · GTBP
-
Material Financial Restatement
The company restated its Q3 2025 financial statements to correct material errors related to the classification of 'Greenshoe Rights' as a liability, significantly impacting reported net losses.
-
Disclosure of Material Weakness
Management concluded that disclosure controls and procedures were ineffective as of September 30, 2025, due to a material weakness in internal control over financial reporting for complex financial transactions.
-
Significant Dilutive Events
Subsequent to the reporting period (October 2025), the company saw further dilution from the exercise of Greenshoe Rights ($1.85 million purchase price) and conversion of 2,556.48 Series L Preferred Stock shares into 4,309,288 common shares, with the conversion price decreasing to $0.5319.
-
Reiterated Going Concern Warning
The company continues to raise substantial doubt about its ability to continue as a going concern, citing sustained operating losses and insufficient cash resources without additional financing.
Analysis · GTBP · Life Sciences
GT Biopharma filed an amended Quarterly Report (10-Q/A) to restate its financial statements for the quarter ended September 30, 2025, due to material errors in classifying 'Greenshoe Rights' as a liability. This correction significantly altered reported net loss figures, changing the three-month period from a loss of $3.1 million to a net income of $8.3 million, and increasing the nine-month net loss from $5.3 million to $22.6 million. The company also disclosed a material weakness in its internal controls over financial reporting related to complex financial transactions. While the company regained NASDAQ compliance for its minimum stockholders' equity, it continues to operate under a going concern warning. Furthermore, subsequent events in October 2025 indicate continued dilution through the exercise of Greenshoe Rights and conversion of Series L Preferred Stock, with the conversion price dropping below the current market price, highlighting ongoing capital structure challenges.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 553 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $0.40 to $3.85. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.